KRAS and pancreatic adenocarcinoma: Three KRAS G12D mutant human pancreatic adenocarcinoma cell lines were tested in conventional 2D cultures for sensitivity to MRTX1133, a specific non-covalent inhibitor of the KRAS G12D protein.